Nicholson Wealth Management Group LLC Boosts Stake in Becton, Dickinson and Company $BDX

Nicholson Wealth Management Group LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,433 shares of the medical instruments supplier’s stock after acquiring an additional 130 shares during the period. Nicholson Wealth Management Group LLC’s holdings in Becton, Dickinson and Company were worth $1,108,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. GAMMA Investing LLC grew its position in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after acquiring an additional 27,581 shares during the period. Dynamic Advisor Solutions LLC grew its position in shares of Becton, Dickinson and Company by 7.7% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 1,406 shares of the medical instruments supplier’s stock valued at $322,000 after acquiring an additional 101 shares during the period. Finally, Ritholtz Wealth Management bought a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $224,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Up 2.1%

Shares of NYSE:BDX opened at $189.20 on Friday. The firm has a fifty day moving average price of $190.60 and a two-hundred day moving average price of $184.92. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a market cap of $54.23 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 1.45 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Analyst Ratings Changes

Several research firms recently commented on BDX. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday. Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $205.40.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 1,838 shares of company stock worth $348,392. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.